EP1375495A1 - Method for producing 2-azetidinone derivative - Google Patents
Method for producing 2-azetidinone derivative Download PDFInfo
- Publication number
- EP1375495A1 EP1375495A1 EP02705071A EP02705071A EP1375495A1 EP 1375495 A1 EP1375495 A1 EP 1375495A1 EP 02705071 A EP02705071 A EP 02705071A EP 02705071 A EP02705071 A EP 02705071A EP 1375495 A1 EP1375495 A1 EP 1375495A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- carbon atoms
- substituent
- compound
- pyridyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 title abstract description 7
- 238000004519 manufacturing process Methods 0.000 title description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 82
- 102000004190 Enzymes Human genes 0.000 claims abstract description 28
- 108090000790 Enzymes Proteins 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 17
- 150000002148 esters Chemical class 0.000 claims abstract description 8
- 230000003301 hydrolyzing effect Effects 0.000 claims abstract description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 75
- 125000001424 substituent group Chemical group 0.000 claims description 57
- 125000000217 alkyl group Chemical group 0.000 claims description 25
- 102000004882 Lipase Human genes 0.000 claims description 22
- 108090001060 Lipase Proteins 0.000 claims description 22
- 125000003545 alkoxy group Chemical group 0.000 claims description 22
- 239000004367 Lipase Substances 0.000 claims description 19
- 235000019421 lipase Nutrition 0.000 claims description 19
- 125000005843 halogen group Chemical group 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 15
- 125000001188 haloalkyl group Chemical group 0.000 claims description 15
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- -1 3-fluoro-2-pyridyl group Chemical group 0.000 claims description 11
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 8
- 244000005700 microbiome Species 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 241000228212 Aspergillus Species 0.000 claims description 3
- 241000589516 Pseudomonas Species 0.000 claims description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 22
- 239000002904 solvent Substances 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 239000000203 mixture Substances 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 13
- 239000013078 crystal Substances 0.000 description 13
- 238000005160 1H NMR spectroscopy Methods 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 239000011369 resultant mixture Substances 0.000 description 12
- 238000001914 filtration Methods 0.000 description 10
- 230000003287 optical effect Effects 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- KQIADDMXRMTWHZ-UHFFFAOYSA-N chloro-tri(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)C(C)C KQIADDMXRMTWHZ-UHFFFAOYSA-N 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- SHGLJKXQNOHXHT-CVEARBPZSA-N [(2r,3s)-2-(3-fluoropyridin-2-yl)-1-(4-methoxyphenyl)-4-oxoazetidin-3-yl] acetate Chemical compound C1=CC(OC)=CC=C1N1C(=O)[C@@H](OC(C)=O)[C@H]1C1=NC=CC=C1F SHGLJKXQNOHXHT-CVEARBPZSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000011877 solvent mixture Substances 0.000 description 3
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 3
- HZDNNJABYXNPPV-UHFFFAOYSA-N (2-chloro-2-oxoethyl) acetate Chemical compound CC(=O)OCC(Cl)=O HZDNNJABYXNPPV-UHFFFAOYSA-N 0.000 description 2
- OZIMPUNGBUYCSP-UHFFFAOYSA-N 3-fluoropyridine-2-carbaldehyde Chemical compound FC1=CC=CN=C1C=O OZIMPUNGBUYCSP-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- KXCGNMBQZIRJTQ-CXUHLZMHSA-N C1=CC(OC)=CC=C1\N=C\C1=NC=CC=C1F Chemical compound C1=CC(OC)=CC=C1\N=C\C1=NC=CC=C1F KXCGNMBQZIRJTQ-CXUHLZMHSA-N 0.000 description 2
- 0 CC1(C)N(C)[C@](*)[C@]1OC1(*)OC1 Chemical compound CC1(C)N(C)[C@](*)[C@]1OC1(*)OC1 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- HKVFISRIUUGTIB-UHFFFAOYSA-O azanium;cerium;nitrate Chemical compound [NH4+].[Ce].[O-][N+]([O-])=O HKVFISRIUUGTIB-UHFFFAOYSA-O 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000010931 ester hydrolysis Methods 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- JBSYDIKKOAPATG-UHFFFAOYSA-N 4-methoxy-n-(4-methoxyphenyl)-n-methylaniline Chemical compound C1=CC(OC)=CC=C1N(C)C1=CC=C(OC)C=C1 JBSYDIKKOAPATG-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/10—Nitrogen as only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
Definitions
- This invention relates to a process for producing a 2-azetidinone derivative.
- 2-Azetidinone derivatives are important as reactive compounds for forming the subsituent at the 13-position of an anticancer compound having the following structure.
- a reactive compound use is made of, for example, a compound (1) having the following structure (TIPS: triisopropylsilyl group, Boc: tertiary butoxycarbonyl group (hereinafter “tertiary” will be abbreviated as “t-”, i.e., “t-butoxycarbonyl group”)
- This compound (1) is obtained by subjecting a racemic compound (2) (PMP: paramethoxyphenyl group (4-methoxyphenyl group) , Ac: acetyl group, the acetoxy group at the 3-position and the 3-fluoro-2-pyridyl group at the 4-position being in the cis-configuration): to deprotection of Ac at the 3-position, conversion into TIPS, recrystallization, elimination of PMP at the 1-position, and separation by column chromatography (which will be sometimes abbreviated as column hereinafter) to give a compound (3): followed by separation with the use of an optical resolution column and attachment of a protective group.
- a racemic compound (2) PMP: paramethoxyphenyl group (4-methoxyphenyl group)
- Ac acetyl group, the acetoxy group at the 3-position and the 3-fluoro-2-pyridyl group at the 4-position being in the cis-configuration
- the process for obtaining the compound (1) from the racemic compound (2) suffers from a problem that troublesome procedures (epimerization, replacement of the solvent for recrystallization, isolation by the column, etc.) are needed and yet only a low yield can be achieved.
- To obtain the compound (1) there arises an additional problem that the compound (3) should be separated by using an optical resolution column in the step prior to the final step, which results in an increase in the cost in case of mass production.
- the present invention aims at providing a production process whereby an optically active 2-azetidinone derivative can be easily produced in a large amount at a low cost.
- the present inventors have found a production process whereby an optically active 2-azetidinone derivative can be efficiently produced in a large amount at a low cost by treating a racemic 2-azetidinone derivative with an enzyme capable of asymmetrically hydrolyzing an ester, thereby completing the present invention.
- the present invention relates to a process for producing a compound represented by formula (II): wherein R 1 represents a phenyl group or a pyridyl group (in which each group may have one or more substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group); R 2 represents a hydrogen atom, a hydroxyl group, an alkoxyl group having 1 to 6 carbon atoms which may have substituent(s), an alkanoyl group having 1 to 6 carbon atoms which may have substituent(s), an alkenoyl group having 2 to 6 carbon atoms which may have substituent(s), an aryl group which may have substituent(s) , an aryloyl group
- the present invention further relates to the followings:
- the compound represented by formula (I) (which will be called the compound (I) hereinafter and the same will apply to compounds represented by other formulae) is treated with an enzyme capable of asymmetrically hydrolyzing an ester (which will be sometimes simply called an "enzyme” hereinafter) to thereby give the compound (II).
- an enzyme capable of asymmetrically hydrolyzing an ester which will be sometimes simply called an "enzyme” hereinafter
- another compound (III) is formed together with the compound (II) as shown in the following reaction scheme.
- the acyloxy group at the 3-position and R 1 at the 4-position are in the cis-configuration.
- the compound (I) is a racemate having the (3R, 4S) and (3S, 4R) forms
- the compound (II) is in the (3R, 4S) form
- the compound (III) is in the (3S, 4R) form. Since the (35, 4R) form of the compound (I) is selectively ester-hydrolyzed by the enzyme, the (3R, 4S) form of the compound (I) , namely, the compound (II) selectively remains.
- the compound (II) may be separated from the mixture of the compound (II) with the compound (III) by usual recrystallization using a suitable solvent without resort to a column. It is advantageous that, even though R 3 COO at the 3-position of the compound (II) is ester-hydrolyzed into OH and a desired protective group is introduced thereinto, the R-configuration at the 3-position and the S-configuration at the 4-position are sustained, and even though the amino group at the 1-position is eliminated or protected, the R-configuration at the 3-position and the S-configuration at the 4-psotion are sustained. Owing to these characteristics, the above-described compound (1) can be formed without resort to optical resolution by using a column, whereby an extremely high efficiency can be established (see, Examples and Referential Examples).
- the enzyme to be used in the present invention is not particularly restricted, so long as it is capable of stereo-selectively hydrolyzing the ester bond at the 3-position of the (3S, 4R) form of the compound (I).
- a higher optical purity of the compound (III) obtained by the above-described reaction brings about the higher ester hydrolysis selectivity of the (3S, 4R) form of the compound (I). Therefore, it is favorable to employ such an enzyme.
- the enzyme to be used in the present invention has an optical purity of the compound (III) of 80%ee or above, still preferably 90%ee or above and particularly preferably 95%ee or above.
- a lipase is preferable. It is still preferable to use a lipase originating in a microorganism, for example, a lipase originating in a microorganism belonging to the genus Pseudomonas or Aspergillus .
- an immobilized lipase examples thereof include lipases immobilized on ceramics or diatomaceous earth.
- lipase As specific examples of the lipase, Amano PS, Amano PS-CI, Amano PS-DI and Amano AK (manufactured by Amano Enzyme), etc. may be cited.
- the contact method is not particularly restricted, it is preferable to dissolve the compound (I) in an appropriate solvent and then bring the enzyme into contact with the compound (I).
- the contact time of bringing the above-described enzyme into contact with the compound (I) may be properly determined to achieve the desired hydrolysis ratio and optical purity.
- the reaction can proceed even if the contact time with the compound (I) is a short time.
- the contact time is preferably 0.5 to 48 hours, more preferably 0.5 to 24 hours, and most preferably 0.5 to 18 hours.
- the solvent is not particularly restricted, so long as it would not inhibit the ester-hydrolysis reaction as described above.
- an organic solvent such as toluene, isopropyl ether, ethyl acetate, ethanol, acetonitrile, isopropyl ether, tetrahydrofuran, acetone, or a mixture thereof with water.
- the mixing ratio (by volume) of water is 5% or more but not more than 80%.
- the mixing ratio of water is preferably adjusted to 40%.
- the reaction temperature may be properly determined depending on the solvent. Namely, the reaction temperature is preferably controlled to about 40°C in case of using an ethyl acetate or toluene-based solvent, or to about 25°C in case of using an ethanol-based solvent.
- Stirring may be performed by using a stirrer, stirring blades, a shaker or the like.
- An adequate device may be suitably selected.
- the relation between the concentration of the substrate, i.e., the compound (I) and the amount of the enzyme may be suitably controlled.
- the selectivity of the enzyme would be lowered with an increase in the substrate concentration.
- the selectively would be lowered with a decrease in the enzyme amount. It is preferable to control the substrate concentration to about 5% and the enzyme amount to about 0.4 (enzyme mass/substrate mass).
- the pH of the reaction system is usually adjusted to the optimum pH value of the enzyme during the reaction.
- the initial pH value little differs from the pH value after the completion of the reaction. Thus, there arises a merit that no pH control is needed.
- the enzyme is filtered off and the solvent is concentrated under reduced pressure. Then the residue is extracted with a solvent, concentrated under reduced pressure and recrystallized from an appropriate solvent.
- the compound (II) can be obtained at a high purity (99% or above) and a high optical purity (99%ee or above).
- Water-containing methanol is preferable as the solvent for crystallization.
- a methanol/water mixture (17:19 by volume) is preferable therefor.
- the compound (II) thus obtained is a novel optically active compound.
- R 1 represents a phenyl group or a pyridyl group which may respectively have one or more substituent (s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group, preferably a halogen atom or an alkoxyl group.
- substituent selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group, preferably a halogen atom or an alkoxyl group.
- R 1 is a 3-fluoro-2-pyridyl group.
- R 2 represents a hydrogen atom, a hydroxyl group, an alkoxyl group having 1 to 6 carbon atoms which may have substituent(s), an alkanoyl group having 1 to 6 carbon atoms which may have substituent(s), an alkenoyl group having 2 to 6 carbon atoms which may have substituent(s), an aryl group which may have substituent (s) , an aryloyl group which may have substituent(s) or an aralkyl group which may have substituent(s).
- R 2 is a phenyl group or an aralkyl group.
- the phenyl group may have one or more substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group, preferably an alkoxyl group.
- the aralkyl group has a structure wherein an alkyl group having 1 to 6 carbon atoms is substituted by one or more aryl group(s), and the aryl moiety may have one or more Substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group.
- R 2 is a 4-methoxyphenyl group or a bis(4-methoxyphenyl)methyl group.
- R 3 represents an alkyl group having 1 to 6 carbon atoms which may have substituent(s) or an alkenyl group having 2 to 6 carbon atoms which may have substituent(s). It is particularly preferable that R 3 is a methyl group.
- Cis-3-acetoxy-4-(3-fluoro-2-pyridyl)-1-(4-methoxyphenyl)-2-azetidinone (480 g) was suspended in a mixture of ethanol (5.76 1) with 0.1 M phosphate buffer pH 7.0 (3.84 1) . Then an enzyme Lipase PS-CI (144 g) was added thereto and the mixture was stirred at 25°C for 16 hours. After evaporating ethanol, the residue was extracted with methylene chloride and the organic layer was evaporated. To the obtained residue were added methanol (8.16 1) and water (9.18 1) and the mixture was stirred at 10°C for 16 hours.
- Example 1a (3R,4S)-cis-3-acetoxy-4-(3-fluoro-2-pyridyl)-1-(4-methoxyphenyl)-2-azetidinone
- Cis-3-acetoxy-4-(3-fluoro-2-pyridyl)-1-(4-methoxyphenyl) -2-azetidinone (1 g) was suspended in a mixture of ethanol (6 ml) with 0.1 M phosphate buffer pH 7.0 (4 ml). Then an enzyme Lipase PS-CI (1 g) was added thereto and the mixture was stirred at 25°C for 30 minutes. After evaporating ethanol, the residue was extracted with methylene chloride and the organic layer was evaporated. To the obtained residue were added methanol (17 ml) and water (19 ml) and the mixture was stirred at 10°C for 16 hours. The crystals thus precipitated were collected by filtration and dried under reduced pressure to thereby give the title compound (400 mg, 99.9%ee) as pale brown crystals. The 1 H-NMR data of this product was identical with those of the compound obtained in Example 1.
- Cis-3-acetoxy-4-(3-fluoro-2-pyridyl)-1- ⁇ bis(4-methoxyphenyl)methyl ⁇ -2-azetidinone 200 mg was suspended in a mixture of N,N-dimethylformamide (2 ml) with 0.1 M phosphate buffer pH 7.0 (18 ml). Then an enzyme Lipase PS-CI (200 mg) was added thereto and the mixture was stirred at 25°C for 2 days. Then the liquid reaction mixture was extracted with methylene chloride. The organic layer was washed with water and dried over anhydrous magnesium sulfate.
- 3-fluoro-2-formylpyridine (6.2 g) and bis(4-methoxyphenyl)methylamine (12 g) were dissolved in toluene (30 ml). After adding anhydrous sodium sulfate (12 g), the resultant mixture was stirred at room temperature for 30 minutes. After filtering off the insoluble matters, the liquid reaction mixture was concentrated under reduced pressure to give an imine compound. A solution (60 ml) of the imine compound thus obtained and triethylamine (8.2 ml) in dichloromethane was cooled to -5°C.
- an optically active compound (II) can be obtained from a racemic compound (I) merely by treating the compound (I) with an enzyme capable of asymmetrically hydrolyzing an ester.
- an enzyme capable of asymmetrically hydrolyzing an ester capable of asymmetrically hydrolyzing an ester.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Description
- This invention relates to a process for producing a 2-azetidinone derivative.
-
-
- This compound (1) is obtained by subjecting a racemic compound (2) (PMP: paramethoxyphenyl group (4-methoxyphenyl group) , Ac: acetyl group, the acetoxy group at the 3-position and the 3-fluoro-2-pyridyl group at the 4-position being in the cis-configuration): to deprotection of Ac at the 3-position, conversion into TIPS, recrystallization, elimination of PMP at the 1-position, and separation by column chromatography (which will be sometimes abbreviated as column hereinafter) to give a compound (3): followed by separation with the use of an optical resolution column and attachment of a protective group.
- The process for obtaining the compound (1) from the racemic compound (2) suffers from a problem that troublesome procedures (epimerization, replacement of the solvent for recrystallization, isolation by the column, etc.) are needed and yet only a low yield can be achieved. To obtain the compound (1), there arises an additional problem that the compound (3) should be separated by using an optical resolution column in the step prior to the final step, which results in an increase in the cost in case of mass production.
- The present invention aims at providing a production process whereby an optically active 2-azetidinone derivative can be easily produced in a large amount at a low cost.
- The present inventors have found a production process whereby an optically active 2-azetidinone derivative can be efficiently produced in a large amount at a low cost by treating a racemic 2-azetidinone derivative with an enzyme capable of asymmetrically hydrolyzing an ester, thereby completing the present invention.
- Accordingly, the present invention relates to a process for producing a compound represented by formula (II): wherein R1 represents a phenyl group or a pyridyl group (in which each group may have one or more substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group); R2 represents a hydrogen atom, a hydroxyl group, an alkoxyl group having 1 to 6 carbon atoms which may have substituent(s), an alkanoyl group having 1 to 6 carbon atoms which may have substituent(s), an alkenoyl group having 2 to 6 carbon atoms which may have substituent(s), an aryl group which may have substituent(s) , an aryloyl group whi ch may have substituent(s) or an aralkyl group which may have substituent(s); and R3 represents an alkyl group having 1 to 6 carbon atoms which may have substituent(s) or an alkenyl group having 2 to 6 carbon atoms which may have substituent(s);
which comprises treating a compound represented by formula (I) with an enzyme capable of asymmetrically hydrolyzing an ester: wherein R1, R2 and R3 are each as defined above. - The present invention further relates to the followings:
- The above-described production process wherein R1 is a 3-fluoro-2-pyridyl group;
- the above-described production process wherein R2 is a a phenyl group (which may have one or more substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group) or an aralkyl group (having a structure wherein an alkyl group having 1 to 6 carbon atoms is substituted by one or more aryl group(s); and said aryl moiety may have one or more substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group);
- the above-described production process wherein R2 is a 4-methoxyphenyl group or a bis (4-methoxyphenyl) methyl group;
- the above-described production process wherein R3 is a methyl group;
- the above-described production process wherein the enzyme is a lipase;
- the above-described production process wherein the lipase is a lipase originating in a microorganism belonging to the genus Pseudomonas;
- the above-described production process wherein the lipase is a lipase originating in a microorganism belonging to the genus Aspergillus;
- the above-described production process wherein the lipase is immobilized;
- a compound represented by formula (II): wherein R1 represents a phenyl group or a pyridyl group (in which each group may have one or more substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group); R2 represents a hydrogen atom, a hydroxyl group, an alkoxyl group having 1 to 6 carbon atoms which may have substituent(s), an alkanoyl group having 1 to 6 carbon atoms which may have substituent(s), an alkenoyl group having 2 to 6 carbon atoms which may have substituent(s), an aryl group which may have substituent(s), an aryloyl group which may have substituent (s) or an aralkyl group which may have substituent(s); and R3 represents an alkyl group having 1 to 6 carbon atoms which may have substituent(s) or an alkenyl group having 2 to 6 carbon atoms which may have substituent(s);
- the above-described compound wherein R1 is a 3-fluoro-2-pyridyl group;
- the above-described compound wherein R2 is a phenyl group (which may have one or more substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group) or an aralkyl group (having a structure wherein an alkyl group having 1 to 6 carbon atoms is substituted by one or more aryl group(s); and said aryl moiety may have one or more substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms , a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group);
- the above-described compound wherein R2 is a 4-methoxyphenyl group or a bis (4-methoxyphenyl) methyl group;
- the above-described compound wherein R3 is a methyl group, etc.
-
- In the present invention, the compound represented by formula (I) (which will be called the compound (I) hereinafter and the same will apply to compounds represented by other formulae) is treated with an enzyme capable of asymmetrically hydrolyzing an ester (which will be sometimes simply called an "enzyme" hereinafter) to thereby give the compound (II). Usually another compound (III) is formed together with the compound (II) as shown in the following reaction scheme.
- It is preferable herein that in the compound (I), the acyloxy group at the 3-position and R1 at the 4-position are in the cis-configuration. In this case, the compound (I) is a racemate having the (3R, 4S) and (3S, 4R) forms, the compound (II) is in the (3R, 4S) form and the compound (III) is in the (3S, 4R) form. Since the (35, 4R) form of the compound (I) is selectively ester-hydrolyzed by the enzyme, the (3R, 4S) form of the compound (I) , namely, the compound (II) selectively remains. In case where the compound (II) has crystalline nature, the compound (II) may be separated from the mixture of the compound (II) with the compound (III) by usual recrystallization using a suitable solvent without resort to a column. It is advantageous that, even though R3COO at the 3-position of the compound (II) is ester-hydrolyzed into OH and a desired protective group is introduced thereinto, the R-configuration at the 3-position and the S-configuration at the 4-position are sustained, and even though the amino group at the 1-position is eliminated or protected, the R-configuration at the 3-position and the S-configuration at the 4-psotion are sustained. Owing to these characteristics, the above-described compound (1) can be formed without resort to optical resolution by using a column, whereby an extremely high efficiency can be established (see, Examples and Referential Examples).
- The enzyme to be used in the present invention is not particularly restricted, so long as it is capable of stereo-selectively hydrolyzing the ester bond at the 3-position of the (3S, 4R) form of the compound (I).
- A higher optical purity of the compound (III) obtained by the above-described reaction brings about the higher ester hydrolysis selectivity of the (3S, 4R) form of the compound (I). Therefore, it is favorable to employ such an enzyme.
- It is preferable that the enzyme to be used in the present invention has an optical purity of the compound (III) of 80%ee or above, still preferably 90%ee or above and particularly preferably 95%ee or above.
- As the enzyme to be used in the present invention, a lipase is preferable. It is still preferable to use a lipase originating in a microorganism, for example, a lipase originating in a microorganism belonging to the genus Pseudomonas or Aspergillus.
- It is also preferable to use an immobilized lipase. Examples thereof include lipases immobilized on ceramics or diatomaceous earth.
- As specific examples of the lipase, Amano PS, Amano PS-CI, Amano PS-DI and Amano AK (manufactured by Amano Enzyme), etc. may be cited.
- To treat the compound (I) wi th the above-described enzyme, it is required to bring the compound (I) into contact wi th the enzyme. Although the contact method is not particularly restricted, it is preferable to dissolve the compound (I) in an appropriate solvent and then bring the enzyme into contact with the compound (I).
- The contact time of bringing the above-described enzyme into contact with the compound (I) may be properly determined to achieve the desired hydrolysis ratio and optical purity. In the present invention, when an immobilized lipase is used as the enzyme, the reaction can proceed even if the contact time with the compound (I) is a short time. Illustratively, the contact time is preferably 0.5 to 48 hours, more preferably 0.5 to 24 hours, and most preferably 0.5 to 18 hours.
- The solvent is not particularly restricted, so long as it would not inhibit the ester-hydrolysis reaction as described above. For example, use can be made of an organic solvent such as toluene, isopropyl ether, ethyl acetate, ethanol, acetonitrile, isopropyl ether, tetrahydrofuran, acetone, or a mixture thereof with water. In case of using a mixture of an organic solvent with water, it is preferable that the mixing ratio (by volume) of water is 5% or more but not more than 80%. In case of using ethanol as the organic solvent, the mixing ratio of water is preferably adjusted to 40%.
- The reaction temperature may be properly determined depending on the solvent. Namely, the reaction temperature is preferably controlled to about 40°C in case of using an ethyl acetate or toluene-based solvent, or to about 25°C in case of using an ethanol-based solvent.
- Stirring may be performed by using a stirrer, stirring blades, a shaker or the like. An adequate device may be suitably selected.
- The relation between the concentration of the substrate, i.e., the compound (I) and the amount of the enzyme may be suitably controlled. In general, the selectivity of the enzyme would be lowered with an increase in the substrate concentration. Also, the selectively would be lowered with a decrease in the enzyme amount. It is preferable to control the substrate concentration to about 5% and the enzyme amount to about 0.4 (enzyme mass/substrate mass).
- The pH of the reaction system is usually adjusted to the optimum pH value of the enzyme during the reaction. In the present invention, the initial pH value little differs from the pH value after the completion of the reaction. Thus, there arises a merit that no pH control is needed.
- After the completion of the enzymatic reaction, the enzyme is filtered off and the solvent is concentrated under reduced pressure. Then the residue is extracted with a solvent, concentrated under reduced pressure and recrystallized from an appropriate solvent. Thus, the compound (II) can be obtained at a high purity (99% or above) and a high optical purity (99%ee or above).
- Water-containing methanol is preferable as the solvent for crystallization. In particular, a methanol/water mixture (17:19 by volume) is preferable therefor.
- The compound (II) thus obtained is a novel optically active compound.
- In the compound (I) and the compound (II), the substituents R1, R2 and R3 remain unchanged after the reaction.
- Next, the substituents R1, R2 and R3 will be illustrated in greater detail.
- R1 represents a phenyl group or a pyridyl group which may respectively have one or more substituent (s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group, preferably a halogen atom or an alkoxyl group.
- It is particularly preferable that R1 is a 3-fluoro-2-pyridyl group.
- R2 represents a hydrogen atom, a hydroxyl group, an alkoxyl group having 1 to 6 carbon atoms which may have substituent(s), an alkanoyl group having 1 to 6 carbon atoms which may have substituent(s), an alkenoyl group having 2 to 6 carbon atoms which may have substituent(s), an aryl group which may have substituent (s) , an aryloyl group which may have substituent(s) or an aralkyl group which may have substituent(s).
- It is preferable that R2 is a phenyl group or an aralkyl group. The phenyl group may have one or more substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group, preferably an alkoxyl group. The aralkyl group has a structure wherein an alkyl group having 1 to 6 carbon atoms is substituted by one or more aryl group(s), and the aryl moiety may have one or more Substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group.
- It is particularly preferable that R2 is a 4-methoxyphenyl group or a bis(4-methoxyphenyl)methyl group.
- R3 represents an alkyl group having 1 to 6 carbon atoms which may have substituent(s) or an alkenyl group having 2 to 6 carbon atoms which may have substituent(s). It is particularly preferable that R3 is a methyl group.
- Now, the present invention will be described in greater detail by reference to the following Examples, but the present invention should not be construed as being limited thereto.
- Optical purity was determined under the following conditions.
Column: ULTRON ES-OVM (150 mm x 4.6 mm), Shinwa Kako
Mobile phase: MeOH:0.02M phosphate buffer pH 7.0=5:95
Flow rate: 1.0 ml/min
Temperature: 40°C
Detection: 254 nm
Retention time: desired (3R, 4S) ester: 17 min, (3S, 4R) ester: 11 min, (3R, 4S) alcohol: 8.3 min, (3R, 4S) alcohol: 9.3 min, trans-alcohol: 11, 31 min - Cis-3-acetoxy-4-(3-fluoro-2-pyridyl)-1-(4-methoxyphenyl)-2-azetidinone (480 g) was suspended in a mixture of ethanol (5.76 1) with 0.1 M phosphate buffer pH 7.0 (3.84 1) . Then an enzyme Lipase PS-CI (144 g) was added thereto and the mixture was stirred at 25°C for 16 hours. After evaporating ethanol, the residue was extracted with methylene chloride and the organic layer was evaporated. To the obtained residue were added methanol (8.16 1) and water (9.18 1) and the mixture was stirred at 10°C for 16 hours. The crystals thus precipitated were collected by filtration and dried under reduced pressure to thereby give the title compound (182 g, 99.7%ee) as pale brown crystals.
1H-MMR (CDCl3)δ: 1.80 (s, 3H) , 3.74 (s, 3H) , 5.72 (d, 1H, J=5.6Hz), 6.09 (d, 1H, J=5.1Hz), 6.77-6.83 (m, 2H), 7.21-7.29 (m, 2H), 7.30-7.33 (m, 1H), 7.41-7.46 (m, 1H), 8.43-8.46 (m, 1H) - Cis-3-acetoxy-4-(3-fluoro-2-pyridyl)-1-(4-methoxyphenyl) -2-azetidinone (1 g) was suspended in a mixture of ethanol (6 ml) with 0.1 M phosphate buffer pH 7.0 (4 ml). Then an enzyme Lipase PS-CI (1 g) was added thereto and the mixture was stirred at 25°C for 30 minutes. After evaporating ethanol, the residue was extracted with methylene chloride and the organic layer was evaporated. To the obtained residue were added methanol (17 ml) and water (19 ml) and the mixture was stirred at 10°C for 16 hours. The crystals thus precipitated were collected by filtration and dried under reduced pressure to thereby give the title compound (400 mg, 99.9%ee) as pale brown crystals. The 1H-NMR data of this product was identical with those of the compound obtained in Example 1.
- Reactions were carried out as in Example 1 but employing different enzymes and reaction solvents in the asymmetric hydrolysis reaction.
Ex. Enzyme Reaction Solvent (water content:5%) Optical Purity of Compound (III) (%ee) Reaction Ratio 2 Amano PS toluene >95 >48 3 Amano PS isopropyl ether 92 42 4 Amano PS-CI ethyl acetate >95 >48 5 Amano PS-CI toluene >95 >48 6 Amano PS-CI ethanol >95 >48 7 Amano PS-CI acetonitrile >95 36 8 Amano PS-CI isopropyl ether 93 32 9 Amano PS-CI tetrahydrofuran >95 37 10 Amano PS-CI acetone 93 29 11 Amano PS-DI toluene 93 26 12 Amano PS-DI ethanol 93 22 13 Amano PS-DI isopropyl ether 91 28 14 Amano AK isopropyl ether 91 35 - Cis-3-acetoxy-4-(3-fluoro-2-pyridyl)-1-{bis(4-methoxyphenyl)methyl}-2-azetidinone (200 mg) was suspended in a mixture of N,N-dimethylformamide (2 ml) with 0.1 M phosphate buffer pH 7.0 (18 ml). Then an enzyme Lipase PS-CI (200 mg) was added thereto and the mixture was stirred at 25°C for 2 days. Then the liquid reaction mixture was extracted with methylene chloride. The organic layer was washed with water and dried over anhydrous magnesium sulfate. After evaporating the solvent, the obtained residue was subjected to silica gel column to thereby give the title compound (90 mg, 99.7%ee) as a colorless oily product. Also, (3S,4R)-cis-3-hydroxy-4-(3-fluoro-2-pyridyl)-1-{bis(4-methoxyphenyl)methyl}-2-azetidinone (96 mg, 99.5%ee) was obtained.
1H-NMR (CDCl3)δ: 1 .75 (s, 3H) , 3.72 (s, 3H) 3.79 (s, 3H) , 5.30 (d, 1H, J=5Hz), 5.91 (s, 1H), 5.93 (d, 1H, J=5Hz), 6.64 (d, 2H, J=8.9Hz), 6.83 (d, 2H, J=8.9Hz), 7.06-7.20 (m, 6H), 8.35-8.42 (m, 1H) - 3-Fluoro-2-formylpyridine (229 g) and paraanisidine (225 g) were dissolved in toluene (2.29 l). After adding anhydrous sodium sulfate (334 g) , the mixture was stirred at room temperature for 1 hour. After filtering off the insoluble matters, the liquid reaction mixture was concentrated under reduced pressure to thereby give the title compound (449 g).
1H-NMR (CDCl3) δ: 3.85 (s, 3H) , 6.96 (d, J=8.9Hz, 2H) , 7.41 (d, J=8.9Hz, 2H), 7.36-7.43 (m, 1H), 7.53 (m, 1H), 8.62 (d, J=4.3Hz, 1H), 8.86 (s, 1H) - A solution (2.29 l) of N-[(E)-(3-fluoro-2-pyridyl)methylidene]-4-methoxyaniline (449 g) and triethylamine (204 g) in dichloromethane was cooled to -10°C. Then acetoxyacetyl chloride (250 g) was added dropwise thereinto and the resultant mixture was stirred at the same temperature for 30 minutes. Then it was heated to room temperature and stirred for 16 hours . The liquid reaction mixture was washed with water and the solvent was concentrated under reduced pressure to thereby give a crude product (723 g). This crude product was recrystallized from a solvent mixture of ethanol (6.91) and ethyl acetate (350 ml) to thereby give the title compound (486 g) as brown crystals.
1H-NMR (CDCl3)δ: 1.80 (s, 3H), 3.74 (s, 3H), 5.72 (d, 1H, J=5.6Hz), 6. 09 (d, 1H, J=5.1Hz), 6.77-6.83 (m, 2H) , 7.21-7.29 (m, 2H) , 7.30-7.33 (m, 1H, 7.41-7 .46 (m, 1H), 8.43-8.46 (m, 1H). - Under a nitrogen gas stream, 3-fluoro-2-formylpyridine (6.2 g) and bis(4-methoxyphenyl)methylamine (12 g) were dissolved in toluene (30 ml). After adding anhydrous sodium sulfate (12 g), the resultant mixture was stirred at room temperature for 30 minutes. After filtering off the insoluble matters, the liquid reaction mixture was concentrated under reduced pressure to give an imine compound. A solution (60 ml) of the imine compound thus obtained and triethylamine (8.2 ml) in dichloromethane was cooled to -5°C. Then acetoxyacetyl chloride (6.3 ml) was added dropwise thereinto and the resultant mixture was stirred at the same temperature for 30 minutes. Then it was heated to room temperature and stirred for 16 hours. The liquid reaction mixture was washed with water and then extracted with chloroform. The organic layers were combined, washed with water and dried over anhydrous magnesium sulfate. After concentrating the solvent under reduced pressure, ethyl acetate (20 ml) and diisopropyl ether (60 ml) were added to the obtained residue. The resultant mixture was stirred at room temperature. The crystals thus precipitated were collected by filtration to thereby give the title compound (21.8 g) as white crystals.
1H-NMR (CDCl3)δ: 1.75 (s, 3H) , 3.72 (s, 3H) , 3.79 (s, 3H) , 5.30 (d, 1H, J=5Hz) , 5.91 (s, 1H) , 5.93 (d, 1H, J=5Hz) , 6.64 (d, 2H, J=8.9Hz), 6.83 (d, 2H, J=8.9Hz), 7.06-7.20 (m, 6H), 8.35-8.42 (m, 1H) - (3R,4S)-cis-3-acetoxy-4-(3-fluoro-2-pyridyl)-1-(4-methoxyphenyl)-2-azetidinone (181 g, 99.7%ee) was dissolved in a solvent mixture of methylene chloride (725 ml) and methanol (725 ml). After adding potassium carbonate (5.43 g) at 0°C, the resultant mixture was stirred at the same temperature for 1 hour. Then Dowex 50 (27 g) was added to the liquid reaction mixture followed by stirring. After filtering off the insoluble matters, the solvent was evaporated. Then toluene was added to the obtained residue and the mixture was azeotropically distilled. Thus, the title compound (157.9 g, 99.7%ee) was obtained as white crystals.
1H-NMR (CDCl3)δ: 3.74 (s, 3H), 5.34 (d, 1H, J=5Hz), 5.62 (dd, 1H, J=5, 1Hz) , 6.78-6.81 (m, 2H) , 7.15-7.38 (m, 3H), 7.52-7.59 (m, 1H) , 8.45-8.47 (m, 1H) - (3R,4S)-cis-3-hydroxy-4-(3-fluoro-2-pyridyl)-1-(4-methoxyphenyl)-2-azetidinone (126.5 g, 99.7%ee) was dissolved in methylene chloride (1.45 1). After adding triisopropylsilyl chloride (118 g) and imidazole (75 g), the resultant mixture was stirred at room temperature for 12 hours. After washing with water, the liquid reaction mixture was dried over anhydrous magnesium sulfate. Then the solvent was evaporated and n-hexane was added to the obtained residue. The mixture was stirred at room temperature for 2 hours and then at 0°C for 2 hours. The crystals thus precipitated were collected by filtration. Thus, the title compound (176 g, 99.7%ee) was obtained as white crystals.
1H-NMR (CDCl3)δ: 0.91-1.06 (m, 21H), 3.74 (s, 3H) , 5.38 (d, 1H, J=5.1Hz), 5 . 50 (d, 1H, J=4.9Hz), 6.78-6.81 (m, 2H) , 7.23-7.30 (m, 3H), 7.35-7.39 (m, 1H), 8.41-8.43 (m, 1H). - (3R,4S)-cis-3-acetoxy-4-(3-fluoro-2-pyridyl)-1-{bis( 4-methoxyphenyl)methyl}-2-azetidinone (90 mg, 99.5%ee) was dissolved in a solvent mixture of tetrahydrofuran (0.3 ml), methanol (0.3. ml) and methylene chloride (0.3 ml). After adding potassium carbonate (2 .3 mg), the resultant mixture was stirred at 0°C for 1 hour and 30 minutes. Then Dowex 50 (10 mg) was added to the liquid reaction mixture followed by stirring for 5 minutes. After filtering off the insoluble matters, the solvent was evaporated. Thus, the title compound (81.6 mg, 99.5%ee) was obtained as a colorless oily product.
1H-NMR (CDCl3)δ: 3.70 (s, 3H) , 3.81 (s, 3H) , 5.08-5.27 (m, 2H), 5.94 (s, 1H), 6.55 (d, 2H, J=8.6Hz), 6.85 (d, 2H, J=8.6Hz), 7.15-7.20 (m, 6H), 8.36-8.41 (m, 1H) - (3R,4S)-cis-3-hydroxy-4-(3-fluoro-2-pyridyl)-1-{bis(4-methoxyphenyl)methyl}-2-azetidinone (81.6 mg, 99.5%ee) was dissolved in methylene chloride (1 ml). After adding triisopropylsilyl chloride (55.3 µl) and imidazole (20.4 mg), the resultant mixture was stirred at room temperature for 16 hours . After washing with water, the liquid reaction mixture was dried over anhydrous magnesium sulfate. Then the solvent was evaporated. Thus, the title compound (112.8 mg, 99.5%ee) was obtained as a colorless oily product.
1H-NMR (CDCl3) δ: 0.62-1:00 (m, 21H) , 3.69 (s, 3H), 3.78 (s, 3H), 5.15 (d, 1H, J=5Hz), 5.29 (d, 2H, J=5Hz), 5.93 (s, 1H), 6.62 (d, 2H, J-8.6Hz), 6.84 (d, 2H, J=8. 6Hz), 7.05-7.19 (m, 3H), 8.31-8.34 (m, 1H) - (3R,4S)-cis-4-(3-fluoro-2-pyridyl)-1-(4-methoxyphenyl)-3-triisopropylsilyloxy-2-azetidinone (167 g, 99.7%ee) was dissolved in acetonitrile (5 1) and then cooled to -10°C. After adding an aqueous solution (5 1) of ammonium cerium nitrate (515 g), the resultant mixture was stirred at the same temperature for 30 minutes. After adding diisopropyl ether, the liquid reaction mixture was washed with water, a 4% aqueous sodium thiosulfate solution and a 2% aqueous sodium hydrogencarbonate solution. After evaporating the solvent, the obtained residue was dissolved in methanol (1.67 l). Then active carbon (167 g) was added and the resultant mixture was stirred at room temperature for 16 hours. After filtering off the active carbon, the solvent was evaporated. To the obtained residue were added ethanol (835 ml) and water (1.25 l). Then the mixture was stirred at room temperature for 5 hours. The crystals thus precipitated were collected by filtration to thereby give the title compound (97.5 g, 99.7%ee) as white crystals.
1H-NMR (CDCl3)δ: 0.89-1.08 (m, 21H), 5.71 (dd, 1H, J=4.8, 1.4Hz), 5.35 (dd, 1H, J=4.9, 1.5Hz) , 6.18 (brs, 1H), 7.22-7.26 (m, 1H), 7.33-7.41 (m, 1H), 8.42-8.44 (m, 1H) - (3R,4S)-cis-4-(3-fluoro-2-pyridyl)-1-{bis(4-methoxyphenyl)methyl}-3-triisopropylsilyloxy-2-azetidinone (112.8 mg, 99.5%ee) was dissolved in acetonitrile (0.56 ml) and then cooled to -10°C. After adding an aqueous solution (4 ml) of ammonium cerium nitrate (346 mg), the resultant mixture was stirred at the same temperature for 30 minutes. After adding chloroform, the liquid reaction mixture was washed with water and dried over anhydrous magnesium sulfate. After evaporating the solvent, the obtained residue was subjected to silica gel column chromatography to thereby give the title compound (59.2 mg, 99.5%ee) as white crystals. The 1H-NMR data of this product was identical with those obtained in Referential Example 8.
- (3R,4S)-cis-4-(3-fluoro-2-pyridyl)-3-triisopropylsilyloxy-2-azetidinone (44.9 g, 99.7%ee) was dissolved in tetrahydrofuran (448.6 ml). After adding 4-dimethylaminopyridine (1.62 g) and di-t-butyl dicarbonate (36.5 ml) at room temperature, the resultant mixture was stirred at the same temperature for 1 hour. After adding n-hexane, the liquid reaction mixture was washed with a 4% aqueous sodium hydrogencarbonate solution and water. The organic layer was dried over anhydrous magnesium sulfate. After evaporating the solvent, the title compound (58.1 g, 99.7%ee) was obtained as a brown oily product.
1H-NMR (CDCl3)δ: 0. 88-1 .02 (21H, m), 1 .44 (9H, s), 5.27 (1H, d, J=5.6Hz), 5.45 (1H, d, J=5.6Hz), 7.23-7.28 (1H, m), 7.34-7.41 (1H, m), 8.41-8.44 (1H, m) - According to the present invention, an optically active compound (II) can be obtained from a racemic compound (I) merely by treating the compound (I) with an enzyme capable of asymmetrically hydrolyzing an ester. Thus, the process of the present invention makes it possible to efficiently obtain the compound (II) in a large amount at a low cost.
Claims (14)
- A process for producing a compound represented by formula (II): wherein R1 represents a phenyl group or a pyridyl group (in which each group may have one or more substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group); R2 represents a hydrogen atom, a hydroxyl group, an alkoxyl group having 1 to 6 carbon atoms which may have substituent(s), an alkanoyl group having 1 to 6 carbon atoms which may have substituent(s), an alkenoyl group having 2 to 6 carbon atoms which may have substituent(s), an aryl group which may have substituent(s), an aryloyl group which may have substituent (s) or an aralkyl group which may have substituent(s); and R3 represents an alkyl group having 1 to 6 carbon atoms which may have substituent(s) or an alkenyl group having 2 to 6 carbon atoms which may have substituent(s);
which comprises treating a compound represented by formula (I) with an enzyme capable of asymmetrically hydrolyzing an ester: wherein R1, R2 and R3 are each as defined above. - The process according to claim 1 wherein R1 is a 3-fluoro-2-pyridyl group.
- The process according to claim 1 or 2 wherein R2 is a phenyl group (which may have one or more substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group) or an aralkyl group (having a structure wherein an alkyl group having 1 to 6 carbon atoms is substituted by one or more aryl group(s); and said aryl moiety may have one or more substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group).
- The process according to any of claims 1 to 3 wherein R2 is a 4-methoxyphenyl group or a bis (4-methoxyphenyl)methyl group.
- The process according to any of claims 1 to 4 wherein R3 is a methyl group.
- The process according to any of claims 1 to 5 wherein the enzyme is a lipase.
- The process according to claim 6 wherein the lipase is a lipase originating in a microorganism belonging to the genus Pseudomonas.
- The process according to claim 6 wherein the lipase is a lipase originating in a microorganism belonging to the genus Aspergillus.
- The process according to claim 7 or 8 wherein the lipase is immobilized.
- A compound represented by formula (II): wherein R1 represents a phenyl group or a pyridyl group (in which each group may have one or more substituent (s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group); R2 represents a hydrogen atom, a hydroxyl group, an alkoxyl group having 1 to 6 carbon atoms which may have substituent(s), an alkanoyl group having 1 to 6 carbon atoms which may have substituent(s), an alkenoyl group having 2 to 6 carbon atoms which may have substituent(s), an aryl group which may have substituent (s) , an aryloyl group which may have substituent (s) or an aralkyl group which may have substituent(s); and R3 represents an alkyl group having 1 to 6 carbon atoms which may have substituent(s) or an alkenyl group having 2 to 6 carbon atoms which may have substituent(s).
- The compound according to claim 10 wherein R1 is a 3-fluoro-2-pyridyl group.
- The compound according to claim 10 or 11 wherein R2 is a phenyl group (which may have one or more substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group) or an aralkyl group (having a structure wherein an alkyl group having 1 to 6 carbon atoms is substituted by one or more aryl group(s); and said aryl moiety may have one or more substituent(s) selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, an alkoxyl group having 1 to 6 carbon atoms, a nitro group, a carbamoyl group and a cyano group).
- The compound according to any of claims 10 to 12 wherein R2 is a 4-methoxyphenyl group or bis(4-methoxyphenyl)methyl group.
- The compound according to any of claims 10 to 13 wherein R3 is a methyl group.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001063840 | 2001-03-07 | ||
JP2001063840 | 2001-03-07 | ||
PCT/JP2002/001969 WO2002070512A1 (en) | 2001-03-07 | 2002-03-04 | Method for producing 2-azetidinone derivative |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1375495A1 true EP1375495A1 (en) | 2004-01-02 |
EP1375495A4 EP1375495A4 (en) | 2005-03-09 |
EP1375495B1 EP1375495B1 (en) | 2008-09-03 |
Family
ID=18922762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02705071A Expired - Lifetime EP1375495B1 (en) | 2001-03-07 | 2002-03-04 | Method for producing a 2-azetidinone derivative |
Country Status (13)
Country | Link |
---|---|
US (1) | US7126003B2 (en) |
EP (1) | EP1375495B1 (en) |
JP (1) | JP4142444B2 (en) |
KR (1) | KR100851515B1 (en) |
CN (1) | CN1266148C (en) |
AT (1) | ATE407130T1 (en) |
DE (1) | DE50212728D1 (en) |
ES (1) | ES2311591T3 (en) |
HK (1) | HK1058668A1 (en) |
MY (1) | MY139322A (en) |
NO (1) | NO20033917L (en) |
TW (1) | TWI311135B (en) |
WO (1) | WO2002070512A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7592343B2 (en) | 2004-09-20 | 2009-09-22 | Xenon Pharmaceuticals Inc. | Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors |
US7767677B2 (en) | 2004-09-20 | 2010-08-03 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
US7777036B2 (en) | 2004-09-20 | 2010-08-17 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as therapeutic agents |
US7829712B2 (en) | 2004-09-20 | 2010-11-09 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase |
US7919496B2 (en) | 2004-09-20 | 2011-04-05 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes |
US7951805B2 (en) | 2004-09-20 | 2011-05-31 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
US8071603B2 (en) | 2004-09-20 | 2011-12-06 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
US8541457B2 (en) | 2005-06-03 | 2013-09-24 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100886805B1 (en) * | 2001-11-29 | 2009-03-05 | 다이이찌 세이야꾸 가부시기가이샤 | Taxane Derivative Crystal and Its Manufacturing Method |
CN100494204C (en) * | 2006-01-12 | 2009-06-03 | 上海交通大学 | Oxidative synthesis of (1'R,3R,4R)-4-acetoxy-3-(1-tert-butyldimethylsiloxyethyl)azetidin-2-one |
US8785669B2 (en) | 2010-06-30 | 2014-07-22 | Gfv, Llc | Taxane compounds, compositions and methods |
US8697892B2 (en) | 2010-06-30 | 2014-04-15 | Gfv, Llc | Taxane compounds, compositions and methods |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0582469A2 (en) * | 1992-08-06 | 1994-02-09 | Wisconsin Alumni Research Foundation | Process for preparing taxol-type compound from beta-lactam precursors |
EP1001036A2 (en) * | 1992-01-15 | 2000-05-17 | E.R. Squibb & Sons, Inc. | Enzymatic processes for resolution of enantiomeric mixtures of compounds useful as intermediates in the preparation of taxanes |
WO2001029245A2 (en) * | 1999-10-18 | 2001-04-26 | Florida State University | ENZYMATIC PROCESS FOR THE RESOLUTION OF ENANTIOMERIC MIXTURES OF β-LACTAMS |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0679559B2 (en) * | 1985-06-06 | 1994-10-12 | 三共株式会社 | Process for producing optically active azetidinone derivative |
FR2688499B1 (en) * | 1992-03-10 | 1994-05-06 | Rhone Poulenc Rorer Sa | PROCESS FOR THE PREPARATION OF BETA-PHENYLISOSERINE AND ITS ANALOGS. |
TW397866B (en) * | 1993-07-14 | 2000-07-11 | Bristol Myers Squibb Co | Enzymatic processes for the resolution of enantiomeric mixtures of compounds useful as intermediates in the preparation of taxanes |
JP3703519B2 (en) * | 1994-05-31 | 2005-10-05 | 株式会社クラレ | Method for producing optically active substance |
JP2779386B2 (en) | 1995-11-01 | 1998-07-23 | 株式会社カンキョー | Total heat exchange ventilator |
DE19605024A1 (en) | 1996-01-31 | 1997-08-07 | Schering Ag | New selective taxanes, processes for their preparation and their pharmaceutical use |
EP0933360A1 (en) * | 1997-12-22 | 1999-08-04 | Pharmachemie B.V. | Synthesis of new beta-lactams |
US6677456B2 (en) * | 1999-10-15 | 2004-01-13 | Daiichi Pharmaceutical Co., Ltd. | Pentacyclic taxan compound |
-
2002
- 2002-03-04 EP EP02705071A patent/EP1375495B1/en not_active Expired - Lifetime
- 2002-03-04 DE DE50212728T patent/DE50212728D1/en not_active Expired - Lifetime
- 2002-03-04 JP JP2002569832A patent/JP4142444B2/en not_active Expired - Lifetime
- 2002-03-04 US US10/469,918 patent/US7126003B2/en not_active Expired - Lifetime
- 2002-03-04 CN CNB028093550A patent/CN1266148C/en not_active Expired - Fee Related
- 2002-03-04 ES ES02705071T patent/ES2311591T3/en not_active Expired - Lifetime
- 2002-03-04 AT AT02705071T patent/ATE407130T1/en not_active IP Right Cessation
- 2002-03-04 WO PCT/JP2002/001969 patent/WO2002070512A1/en active IP Right Grant
- 2002-03-04 KR KR1020037011670A patent/KR100851515B1/en not_active IP Right Cessation
- 2002-03-07 TW TW091104253A patent/TWI311135B/en not_active IP Right Cessation
- 2002-03-07 MY MYPI20020818A patent/MY139322A/en unknown
-
2003
- 2003-09-04 NO NO20033917A patent/NO20033917L/en not_active Application Discontinuation
-
2004
- 2004-02-26 HK HK04101387A patent/HK1058668A1/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1001036A2 (en) * | 1992-01-15 | 2000-05-17 | E.R. Squibb & Sons, Inc. | Enzymatic processes for resolution of enantiomeric mixtures of compounds useful as intermediates in the preparation of taxanes |
EP0582469A2 (en) * | 1992-08-06 | 1994-02-09 | Wisconsin Alumni Research Foundation | Process for preparing taxol-type compound from beta-lactam precursors |
WO2001029245A2 (en) * | 1999-10-18 | 2001-04-26 | Florida State University | ENZYMATIC PROCESS FOR THE RESOLUTION OF ENANTIOMERIC MIXTURES OF β-LACTAMS |
Non-Patent Citations (1)
Title |
---|
See also references of WO02070512A1 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7592343B2 (en) | 2004-09-20 | 2009-09-22 | Xenon Pharmaceuticals Inc. | Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors |
US7767677B2 (en) | 2004-09-20 | 2010-08-03 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
US7777036B2 (en) | 2004-09-20 | 2010-08-17 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as therapeutic agents |
US7829712B2 (en) | 2004-09-20 | 2010-11-09 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase |
US7919496B2 (en) | 2004-09-20 | 2011-04-05 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes |
US7951805B2 (en) | 2004-09-20 | 2011-05-31 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
US8026360B2 (en) | 2004-09-20 | 2011-09-27 | Xenon Pharmaceuticals Inc. | Substituted pyridazines as stearoyl-CoA desaturase inhibitors |
US8071603B2 (en) | 2004-09-20 | 2011-12-06 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
US8541457B2 (en) | 2005-06-03 | 2013-09-24 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors |
Also Published As
Publication number | Publication date |
---|---|
HK1058668A1 (en) | 2004-05-28 |
NO20033917D0 (en) | 2003-09-04 |
US20040072309A1 (en) | 2004-04-15 |
ATE407130T1 (en) | 2008-09-15 |
MY139322A (en) | 2009-09-30 |
WO2002070512A1 (en) | 2002-09-12 |
EP1375495B1 (en) | 2008-09-03 |
KR100851515B1 (en) | 2008-08-11 |
NO20033917L (en) | 2003-10-31 |
US7126003B2 (en) | 2006-10-24 |
KR20030080072A (en) | 2003-10-10 |
CN1266148C (en) | 2006-07-26 |
JP4142444B2 (en) | 2008-09-03 |
CN1507443A (en) | 2004-06-23 |
EP1375495A4 (en) | 2005-03-09 |
JPWO2002070512A1 (en) | 2004-07-02 |
ES2311591T3 (en) | 2009-02-16 |
TWI311135B (en) | 2009-06-21 |
DE50212728D1 (en) | 2008-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1375495B1 (en) | Method for producing a 2-azetidinone derivative | |
JP2012211136A (en) | Improved method for preparing 3-hydroxy-4-hydroxymethyl pyrrolidine compound | |
KR100914396B1 (en) | Process for the preparation of benzoxazine derivatives and intermediates therefor | |
JP2011510038A (en) | Production method using ((2S, 4R) -4,6-dihydroxytetrahydro-2H-pyran-2-yl) methylcarboxylate and 2-deoxyribose-5-phosphate aldolase | |
JPH0679559B2 (en) | Process for producing optically active azetidinone derivative | |
JPH06172276A (en) | Manufacture of taxol compound from beta - lactam precursor | |
US5527916A (en) | Pyranones | |
JP2005176758A (en) | Method for producing 4-oxochroman-2-carboxylic acid derivative having optical activity | |
JP5216762B2 (en) | Stereoselective synthesis of (S) -1-methyl-phenylpiperazine | |
US5731464A (en) | Process for preparation of indenol | |
KR101399551B1 (en) | Processes for the preparations of optically active cyclopentenones and cyclopentenones prepared therefrom | |
EP1283200A2 (en) | Optically pure paroxetine precursors | |
US6020174A (en) | Chemoenzymatic synthesis of the taxol C-13 side chain N-benzolyl- (2R,3S)-Phenylisoserine | |
RU2414459C2 (en) | Method of producing diaryl cycloalkyl derivatives | |
JPS62272983A (en) | Production of l-(-)-carnitine chloride starting from 3, 4-epoxybutyric ester | |
KR20030074851A (en) | Resolution of chiral compounds using aminocyclopentadienyl ruthenium catalysts | |
JP2666890B2 (en) | Method for producing optically active (+)-4,4,4-trifluoro-3- (indole-3-) butyric acid | |
KR20060060730A (en) | Enzymatic Synthesis of Enantio Pure Intermediates by Cholesterol Esterases from Yeast | |
KR100359028B1 (en) | Method for preparing chiral allyl ester | |
JPH08322591A (en) | Method for obtaining optically pure 1,2,3,4-tetrahydroquinoline-2-acetic acid esters by optical resolution | |
JPH05279370A (en) | Optically active camptothecin derivative and its production | |
US6037166A (en) | Enzymatic kinetic resolution of an intermediate useful for preparing substituted tricyclics | |
AU2004219845A1 (en) | Stereoselective chemoenzymatic process for the preparation of optically enriched phenylglycidates as precursors of taxol side chain | |
JPS6349099A (en) | Production of optically active 3-chloro-4-hydroxy-2-cyclopentenone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030905 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1058668 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20050121 |
|
17Q | First examination report despatched |
Effective date: 20061127 |
|
RTI1 | Title (correction) |
Free format text: METHOD FOR PRODUCING A 2-AZETIDINONE DERIVATIVE |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: DAIICHI SANKYO COMPANY, LIMITED |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: BOVARD AG PATENTANWAELTE Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: GERMAN |
|
REF | Corresponds to: |
Ref document number: 50212728 Country of ref document: DE Date of ref document: 20081016 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1058668 Country of ref document: HK |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080903 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2311591 Country of ref document: ES Kind code of ref document: T3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080903 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FD4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080903 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090203 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080903 |
|
26N | No opposition filed |
Effective date: 20090604 |
|
BERE | Be: lapsed |
Owner name: DAIICHI SANKYO COMPANY, LTD Effective date: 20090331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081203 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090304 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081204 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: DAIICHI SANKYO COMPANY, LIMITED Free format text: DAIICHI SANKYO COMPANY, LIMITED#3-5-1, NIHOMBASHI-HONCHO CHUO-KU#TOKYO 103-8426 (JP) -TRANSFER TO- DAIICHI SANKYO COMPANY, LIMITED#3-5-1, NIHOMBASHI-HONCHO CHUO-KU#TOKYO 103-8426 (JP) |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090304 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080903 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080903 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 16 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20210113 Year of fee payment: 20 Ref country code: CH Payment date: 20210317 Year of fee payment: 20 Ref country code: IE Payment date: 20210310 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20210216 Year of fee payment: 20 Ref country code: GB Payment date: 20210225 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20210406 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20210211 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 50212728 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20220303 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MK9A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20220303 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20220624 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20220304 Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20220305 |